Asterias Biotherapeutics, Inc. (NYSE: AST) today announced that it has entered into an exclusive license agreement with The Regents of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AJuly 12, 2018 7:00 AM Pre-Open Movers 07/11: (AST) (VSAR) (SCYX) Higher; (VOXX) (IOTS) (ANGO) Lower (more...)July 11, 2018 9:19 AM Asterias Biotherapeutics (AST) Set to Open Higher by 50% Following Positive Outcome from Safety Review Committee for AST-VAC2July 11, 2018 7:26 AM Asterias Biotherapeutics (AST) Reports Positive Outcome from Safety Review Committee for AST-VAC2July 11, 2018 7:03 AM